The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Abstract
After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent advances in our understanding of the neurobiology of psychedelics, such as lysergic acid diethylamide (LSD), psilocybin and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders. Recent behavioural and neuroimaging data show that psychedelics modulate neural circuits that have been implicated in mood and affective disorders, and can reduce the clinical symptoms of these disorders. These findings raise the possibility that research into psychedelics might identify novel therapeutic mechanisms and approaches that are based on glutamate-driven neuroplasticity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been suggested that the persisting therapeutic effects of psychedelics are attributable to a similar biological mechanism (39, 40).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [39]
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“5 mg per kg), and this effect was sustained for at least 72 hour”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Dissociative anaesthetics mimic the positive and the negative symptoms (social withdrawal and apathy) of schizophrenia through antagonism at NMDA ( N -methyl- D -aspartate) glutamate receptor”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“Systemic administration of non-competitive NMDA antagonists, such as ketamine, PCP and MK-801 (also known as dizocilpine), in rats markedly increases glutamate release in the mPF”
BackgroundDavis, H. S. (1966) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1966.03100200106038 · Cited by 1,719
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“and was rated as among the most personally meaningful experience”
Background(1990) · Springer eBooks · doi:10.1007/978-3-642-74034-3 · Cited by 1,523
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
(2009) · Elsevier eBooks · doi:10.1016/c2009-1-03742-3 · Cited by 1,308
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 1×
“These effects are probably due to a blockade of NMDA receptors on GABA (γ-aminobutyric acid)-ergic interneuron”
BackgroundNew insights into BDNF function in depression and anxiety
Martinowich, K., Manji, H., & Lu, B. (2007) · Nature Neuroscience · doi:10.1038/nn1971 · Cited by 1,221 · cited 1×
“Deficits in these neuroplastic mechanisms have been implicated in the pathophysiology of depressio”
BackgroundNichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Sheline, Y. I., Barch, D. M., Donnelly, J. M., Ollinger, J. M., Snyder, A. Z., & Mintun, M. A. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01263-x · Cited by 1,191 · cited 1×
“, and attenuates the amygdala response to the presentation of images showing sad faces in patients with depressio”
BackgroundNMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders
Lau, C. G., & Zukin, R. S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2153 · Cited by 1,159
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Johnstone, T., van Reekum, C. M., Urry, H. L., Kalin, N. H., & Davidson, R. J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2063-07.2007 · Cited by 1,051 · cited 1×
“show reduced PFC activity when executive control is engaged, and might suffer from decreased top-down inhibition of amygdala activit”
BackgroundPsilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018 · cited 1×
“Importantly, administration of the 5-HT 2A receptor antagonist ketanserin abolishes virtually all of the psilocybin-induced subjective effects in human”
BackgroundSelf-citationReversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006
Amat, J., Baratta, M. V., Paul, E., Bland, S. T., Watkins, L. R., & Maier, S. F. (2005) · Nature Neuroscience · doi:10.1038/nn1399 · Cited by 931 · cited 1×
“Indeed, recent studies showed that prefrontal 5-HT 2A receptors located on descending projections that control serotonergic activity in the dorsal raphe are involved in stress response”
BackgroundGonzález-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Sanacora, G., Zarate, C. A., Krystal, J. H., & Manji, H. K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2462 · Cited by 894 · cited 1×
“Ketamine therapy could be extended to other disorders in which NMDA receptors are implicated in the pathophysiology — for example, bipolar disorde”
BackgroundTrait anxiety and impoverished prefrontal control of attention.
Bishop, S. J. (2009) · Nature Neuroscience · doi:10.1038/nn.2242 · Cited by 869
Hasler, G., van der Veen, J. W., Tumonis, T., Meyers, N., Shen, J., & Drevets, W. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.193 · Cited by 846
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789
Fu, C. H. Y., Williams, S. C. R., Cleare, A. J., Brammer, M. J., Walsh, N. D., Kim, J., Andrew, C. M., Pich, E. M., Williams, P. M., Reed, L. J., et al. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.9.877 · Cited by 775 · cited 1×
“, and attenuates the amygdala response to the presentation of images showing sad faces in patients with depressio”
BackgroundCognitive therapy versus medication for depression: treatment outcomes and neural mechanisms
DeRubeis, R. J., Siegle, G. J., & Hollon, S. D. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2345 · Cited by 690
Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression
aan het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L., Charney, D. S., & Mathew, S. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.08.038 · Cited by 690
The Early Symptoms of Schizophrenia
Chapman, J. (1966) · British Journal of Psychiatry · doi:10.1192/bjp.112.484.225 · Cited by 675 · cited 1×
“— that are also seen in naturally occurring psychose”
BackgroundEvidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & McKenney, J. D. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 631
Newcome, F. (1968) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.31.4.409-c · Cited by 629
Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600
The Standardized Psychometric Assessment of Altered States of Consciousness (ASCs) in Humans
Dittrich, A. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979351 · Cited by 577
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532
Self-citationPreskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518 · cited 1×
“Likewise, the behavioural effects of selective NR2B antagonists — such as CP-101,606 (also known as Traxoprodil), which produces dose-dependent psychotropic effects similar to those of ketamine in human”
BackgroundCorticotropin-releasing factor receptors 1 and 2 in anxiety and depression
Reul, J. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00117-5 · Cited by 516 · cited 1×
“Stress elevates corticotropin-releasing factor (CRF”
AGHAJANIAN, G. K., & MAREK, G. J. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00051-8 · Cited by 514
Celada, P., Puig, M. V., Casanovas, J. M., Guillazo, G., & Artigas, F. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-24-09917.2001 · Cited by 497 · cited 1×
“For example, activation of 5-HT 2A receptors in the mPFC increases the firing rate of 5-HT neurons in the dorsal raphe and of dopamine neurons in the VTA, resulting in an increased release of 5-HT in the mPF”
BackgroundVaidya, V. A., Marek, G. J., Aghajanian, G. K., & Duman, R. S. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02785.1997 · Cited by 479 · cited 1×
“and to increase BDNF levels in prefrontal and limbic brain areas in rat”
BackgroundHasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451
Self-citationNeurocognitive Mechanisms in Depression: Implications for Treatment
Clark, L., Chamberlain, S. R., & Sahakian, B. J. (2009) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.31.060407.125618 · Cited by 446
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444
Self-citationJackson, M. E., Homayoun, H., & Moghaddam, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308455101 · Cited by 430 · cited 1×
“concomitant with an increase in the firing rate of pyramidal neurons in this are”
BackgroundEffects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors.
Oye, I., Paulsen, O., & Maurset, A. (1992) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)11430-4 · Cited by 429
Serotonin research: contributions to understanding psychoses
GEYER, M., & VOLLENWEIDER, F. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.06.006 · Cited by 427 · cited 1×
“— that are also seen in naturally occurring psychose”
BackgroundSelf-citationAnand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A., & Krystal, J. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.270 · Cited by 426
Cortical 5-HT 2A Receptor Signaling Modulates Anxiety-Like Behaviors in Mice
Weisstaub, N. V., Zhou, M., Lira, A., Lambe, E., González-Maeso, J., Hornung, J.-P., Sibille, E., Underwood, M., Itohara, S., Dauer, W. T., et al. (2006) · Science · doi:10.1126/science.1123432 · Cited by 425
Vollenweider, F. X., Leenders, K. L., Øye, I., Hell, D., & Angst, J. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00042-9 · Cited by 413
Self-citationGlutamate-based antidepressants: 20 years on
Skolnick, P., Popik, P., & Trullas, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.002 · Cited by 380
Aghajanian, G. K., & Marek, G. J. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01224-x · Cited by 374
Aghajanian, G. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00135-3 · Cited by 371 · cited 1×
“This increase in glutamatergic synaptic activity was initially thought to result from stimulation of presynaptic 5-HT 2A receptors located on glutamatergic thalamocortical afferents to the PF”
BackgroundA REVIEW OF THE CLINICAL EFFECTS OF PSYCHOTOMIMETIC AGENTS
Osmond, H. (1957) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1957.tb40738.x · Cited by 365
Vollenweider, F. X., Leenders, K. L., Scharfetter, C., Antonini, A., Maguire, P., Missimer, J., & Angst, J. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00039-9 · Cited by 353 · cited 1×
“Furthermore, and congruent with these findings, human neuroimaging studies have shown that both psilocybin and ketamine markedly activate prefrontal cortical areas, including the ACC and insula and, to a lesser extent, temporal and parieto-occipital region”
ResultSelf-citationSimner, J. (2009) · Cited by 338
Neural Mechanisms Underlying Selective Attention to Threat
Bishop, S. J. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1417.016 · Cited by 329 · cited 1×
“show reduced PFC activity when executive control is engaged, and might suffer from decreased top-down inhibition of amygdala activit”
BackgroundAndrews, A. M., Gerhardt, G. A., Daws, L. C., Shoaib, M., Mason, B. J., Heyser, C. J., De Lecea, L., Balster, R. L., Walsh, S., Dahmen, M. M., et al. (2010) · Encyclopedia of Psychopharmacology · doi:10.1007/978-3-540-68706-1_4410 · Cited by 322
Walter, M., Henning, A., Grimm, S., Schulte, R. F., Beck, J., Dydak, U., Schnepf, B., Boeker, H., Boesiger, P., & Northoff, G. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.39 · Cited by 306 · cited 1×
“Reduced prefrontal glutamate levels that are associated with attenuated PFC activation in response to emotional stimul”
BackgroundVollenweider, F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00108-0 · Cited by 305
Self-citationMathew, S. J., Murrough, J. W., aan het Rot, M., Collins, K. A., Reich, D. L., & Charney, D. S. (2010) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000169 · Cited by 294
Fischer, R. (1971) · Science · doi:10.1126/science.174.4012.897 · Cited by 280
Salvadore, G., Cornwell, B. R., Colon-Rosario, V., Coppola, R., Grillon, C., Zarate, C. A., & Manji, H. K. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.014 · Cited by 277 · cited 1×
“and increased activation of the ACC during an emotional facial processing tas”
BackgroundKetamine and the next generation of antidepressants with a rapid onset of action
Machado-Vieira, R., Salvadore, G., DiazGranados, N., & Zarate, C. A. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.02.010 · Cited by 276 · cited 1×
“Normalization of these neuroplastic deficits might contribute not only to the relatively sustained antidepressant effects of ketamin”
BackgroundDysfunctional Attitudes and 5-HT2 Receptors During Depression and Self-Harm
Meyer, J. H., McMain, S., Kennedy, S. H., Korman, L., Brown, G. M., DaSilva, J. N., Wilson, A. A., Blak, T., Eynan-Harvey, R., Goulding, V. S., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.1.90 · Cited by 264
Response of cluster headache to psilocybin and LSD
Sewell, R. A., Halpern, J. H., & Pope, H. G. (2006) · Neurology · doi:10.1212/01.wnl.0000219761.05466.43 · Cited by 259 · cited 1×
“Finally, another recent study reported that psilocybin and LSD aborted attacks, terminated the cluster period or extended the remission period in people suffering from cluster headache”
Psychedelic Drugs Reconsidered
Seelye, E. E. (1980) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1980.34.4.593 · Cited by 258
Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up
Krupitsky, E., Burakov, A., Romanova, T., Dunaevsky, I., Strassman, R., & Grinenko, A. (2002) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(02)00275-1 · Cited by 246 · cited 1×
“Follow-up studies in the first 2 years revealed a higher rate of abstinence, greater and longer-lasting reductions in craving, and a positive change in nonverbal, unconscious emotional attitude in subjects who had been treated with a high dose, compared with a low dose, of ketamin”
ResultInteractive effects of subanesthetic ketamine and haloperidol in healthy humans
Krystal, J. H., D'Souza, D. C., Karper, L. P., Bennett, A., Abi-Dargham, A., Abi-Saab, D., Cassello, K., Bowers Jr., M. B., Vegso, S., Heninger, G. R., et al. (1999) · Psychopharmacology · doi:10.1007/s002130051049 · Cited by 243
Frokjaer, V. G., Mortensen, E. L., Nielsen, F. Å., Haugbol, S., Pinborg, L. H., Adams, K. H., Svarer, C., Hasselbalch, S. G., Holm, S., Paulson, O. B., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.07.009 · Cited by 242 · cited 1×
“In humans, fronto-limbic 5-HT 2A receptor density is correlated not only with anxiety but also with an individual's difficulties in coping with stres”
Psychedelic Drugs Reconsidered
Grinspoon, L., & Bakalar, J. B. (1979) · Medical Entomology and Zoology · Cited by 239
Garcia, L. S. B., Comim, C. M., Valvassori, S. S., Réus, G. Z., Stertz, L., Kapczinski, F., Gavioli, E. C., & Quevedo, J. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.01.004 · Cited by 237 · cited 1×
“and to increase BDNF levels in prefrontal and limbic brain areas in rat”
BackgroundAgonist-directed signaling of the serotonin 2A receptor depends on β-arrestin-2 interactions in vivo
Schmid, C. L., Raehal, K. M., & Bohn, L. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708862105 · Cited by 229
Béïque, J.-C., Imad, M., Mladenovic, L., Gingrich, J. A., & Andrade, R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700436104 · Cited by 229 · cited 1×
“Several studies have demonstrated that activation of 5-HT 2A receptors by classical hallucinogens or by serotonin leads to a robust, glutamate-dependent increase in the activity of pyramidal neurons, preferentially those in layer V of the prefrontal cortex (PFC”
BackgroundRapid modulation of spine morphology by the 5-HT 2A serotonin receptor through kalirin-7 signaling
Jones, K. A., Srivastava, D. P., Allen, J. A., Strachan, R. T., Roth, B. L., & Penzes, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905884106 · Cited by 226 · cited 1×
“For example, in rats a single dose of the hallucinogen DOI transiently increased the dendritic spine size in cortical neuron”
BackgroundFunctional Coupling of the Amygdala in Depressed Patients Treated with Antidepressant Medication
Chen, C.-H., Suckling, J., Ooi, C., Fu, C. H. Y., Williams, S. C. R., Walsh, N. D., Mitterschiffthaler, M. T., Pich, E. M., & Bullmore, E. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301593 · Cited by 224 · cited 1×
“Conversely, chronic treatment with selective serotonin reuptake inhibitors (SSRIs) increases the functional connectivity between the amygdala and the PF”
BackgroundVollenweider, F. X., Vontobel, P., Øye, I., Hell, D., & Leenders, K. L. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00031-x · Cited by 223
Self-citationPuig, M. V. (2003) · Cerebral Cortex · doi:10.1093/cercor/13.8.870 · Cited by 222 · cited 1×
“Several studies have demonstrated that activation of 5-HT 2A receptors by classical hallucinogens or by serotonin leads to a robust, glutamate-dependent increase in the activity of pyramidal neurons, preferentially those in layer V of the prefrontal cortex (PFC”
BackgroundThe experimental use of psychedelic (LSD) psychotherapy.
Pahnke, W. N. (1970) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1970.03170240060010 · Cited by 220 · cited 1×
“Indeed, it has been shown that the transcendent peak (mystical-type) experience, which has a key role in the therapeutic outcome in psychedelic therap”
BackgroundGouzoulis-Mayfrank, E. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00089-x · Cited by 219 · cited 1×
“Furthermore, and congruent with these findings, human neuroimaging studies have shown that both psilocybin and ketamine markedly activate prefrontal cortical areas, including the ACC and insula and, to a lesser extent, temporal and parieto-occipital region”
ResultSalvadore, G., Cornwell, B. R., Sambataro, F., Latov, D., Colon-Rosario, V., Carver, F., Holroyd, T., DiazGranados, N., Machado-Vieira, R., Grillon, C., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.24 · Cited by 218
Bhagwagar, Z., Hinz, R., Taylor, M., Fancy, S., Cowen, P., & Grasby, P. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1580 · Cited by 214
LSD-Assisted Psychotherapy in Patients with Terminal Cancer
Grof, S., Goodman, L. E., Richards, W. A., & Kurland, A. A. (2017) · International Pharmacopsychiatry · doi:10.1159/000467984 · Cited by 209
Varty, G. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00072-4 · Cited by 202
Breier, A., Adler, C. M., Weisenfeld, N., Su, T.-P., Elman, I., Picken, L., Malhotra, A. K., & Pickar, D. (1998) · Synapse · doi:10.1002/(sici)1098-2396(199806)29:2<142::aid-syn5>3.0.co;2-7 · Cited by 201 · cited 1×
“Specifically, in two studies in humans, ketamine-induced striatal dopamine release correlated with the extent of ketamine-induced psychotic symptom”
BackgroundCRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling
Magalhaes, A. C., Holmes, K. D., Dale, L. B., Comps-Agrar, L., Lee, D., Yadav, P. N., Drysdale, L., Poulter, M. O., Roth, B. L., Pin, J.-P., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2529 · Cited by 198 · cited 1×
“, and administration of CRF into the mPFC of mice enhanced anxiety-like behaviour in response to DOI through sensitization of 5-HT 2 receptor signalling in the PF”
Phelps, L. E., Brutsche, N., Moral, J. R., Luckenbaugh, D. A., Manji, H. K., & Zarate, C. A. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.09.029 · Cited by 189
López-Gil, X., Babot, Z., Amargós-Bosch, M., Suñol, C., Artigas, F., & Adell, A. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301356 · Cited by 183
How can we realize the promise of personalized antidepressant medicines?
Holsboer, F. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2453 · Cited by 177 · cited 1×
“Moreover, the use of biomarkers that are rooted in psychopathology, neuropsychology and/or genetics might help to predict whether ketamine therapy will be appropriate for a given patient with depressio”
BackgroundKargieman, L., Santana, N., Mengod, G., Celada, P., & Artigas, F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704848104 · Cited by 168 · cited 1×
“have a similar effect in enhancing extracellular glutamate release in the PFC, leading to increased activation of pyramidal cell”
BackgroundBenneyworth, M. A., Xiang, Z., Smith, R. L., Garcia, E. E., Conn, P. J., & Sanders‐Bush, E. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.035170 · Cited by 163 · cited 1×
“and positive allosteric modulators of metabotropic glutamate receptor 2 (mGluR2”
BackgroundLecca, S., Melis, M., Luchicchi, A., Ennas, M. G., Castelli, M. P., Muntoni, A. L., & Pistis, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.190 · Cited by 160
Marek, G. J., Wright, R. A., Gewirtz, J. C., & Schoepp, D. D. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00199-3 · Cited by 158
Shelton, R. C., Sanders‐Bush, E., Manier, D. H., & Lewis, D. A. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.11.036 · Cited by 158
(1969) · PubMed · Cited by 150
Brain mechanisms of hallucinogens and entactogens
Vollenweider, F. X. (2001) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2001.3.4/fxvollenweider · Cited by 148
Self-citationResidential Psychedelic (LSD) Therapy for the Narcotic Addict: A Controlled Study
Savage, C. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.01750360040005 · Cited by 148
Psychedelic drugs and mystical experience.
Pahnke, W. N. (1969) · PubMed · Cited by 138
Scruggs, J. L., Schmidt, D. E., & Deutch, A. Y. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00547-0 · Cited by 138 · cited 1×
“This modulation is evidenced by the observation in rats that hallucinogen”
BackgroundÇavuş, I., & Duman, R. S. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00236-1 · Cited by 135 · cited 1×
“and to increase BDNF levels in prefrontal and limbic brain areas in rat”
BackgroundThe Use of LSD in Psychotherapy and Alcoholism
Blaine, G. B. (1968) · Psychosomatic Medicine · doi:10.1097/00006842-196807000-00014 · Cited by 135
Marona‐Lewicka, D., Thisted, R. A., & Nichols, D. E. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2183-9 · Cited by 134 · cited 1×
“In contrast to the tryptamines, the ergolines also show high intrinsic activity at dopamine D2 receptors and at α-adrenergic receptor”
ResultVollenweider, F. X. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979353 · Cited by 130
Self-citationMuschamp, J. W., Regina, M. J., Hull, E. M., Winter, J. C., & Rabin, R. A. (2004) · Brain Research · doi:10.1016/j.brainres.2004.07.044 · Cited by 129 · cited 1×
“This modulation is evidenced by the observation in rats that hallucinogen”
BackgroundJodo, E., Suzuki, Y., Katayama, T., Hoshino, K.-Y., Takeuchi, S., Niwa, S., & Kayama, Y. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhh168 · Cited by 124 · cited 1×
“in cortical and/or subcortical structures and to the subsequent reduction of inhibitory control over prefrontal glutamatergic neuron”
BackgroundVázquez, P. M., Cortés, R., & Artigas, F. (2008) · Cerebral Cortex · doi:10.1093/cercor/bhn204 · Cited by 119
Sipes, T. E., & Geyer, M. A. (1995) · Behavioural Pharmacology · doi:10.1097/00008877-199512000-00010 · Cited by 117
Psychiatric safety of ketamine in psychopharmacology research
Perry, E. B., Cramer, J. A., Cho, H.-S., Petrakis, I. L., Karper, L. P., Genovese, A., O’Donnell, E., Krystal, J. H., D’Souza, D. C., & Yale Ketamine Study Group (2007) · Psychopharmacology · doi:10.1007/s00213-007-0706-2 · Cited by 117
EFFECTS OF MESCALINE AND LYSERGIC ACID (d-LSD-25)
Hoch, P. H., CATTELL, J. P., & Pennes, H. H. (1952) · American Journal of Psychiatry · doi:10.1176/ajp.108.8.579 · Cited by 116
Prance, G. T. (1979) · Cited by 113
Leuner, H. (1962) · Monographien aus dem Gesamtgebiete der Neurologie und Psychiatrie · doi:10.1007/978-3-642-86258-8 · Cited by 112
LSD in the Treatment of Alcoholics*
Kurland, A. A., Savage, C., Pahnke, W. N., Grof, S., & Olsson, J. E. (1971) · Pharmacopsychiatry · doi:10.1055/s-0028-1094301 · Cited by 111 · cited 1×
“Indeed, it has been shown that the transcendent peak (mystical-type) experience, which has a key role in the therapeutic outcome in psychedelic therap”
BackgroundAcute Adverse Reactions to Lsd in Clinical and Experimental use in the United Kingdom
Malleson, N. (1971) · British Journal of Psychiatry · doi:10.1192/bjp.118.543.229 · Cited by 111 · cited 1×
“In fact, by 1965 there were more than 1,000 published clinical studies that reported promising therapeutic effects in over 40,000 subject”
Background5HT-2 mediation of acute behavioral effects of hallucinogens in rats
Wing, L. L., Tapson, G. S., & Geyer, M. A. (1990) · Psychopharmacology · doi:10.1007/bf02244617 · Cited by 107
(1969) · doi:10.1176/ajp.125.10.1352 · Cited by 106
Lukkes, J. L., Vuong, S. M., Scholl, J. L., Oliver, H. A., & Forster, G. L. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.0854-09.2009 · Cited by 98
Large, C. H. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107077712 · Cited by 98
Jentsch, J. D., Tran, A., Taylor, J. R., & Roth, R. H. (1998) · Psychopharmacology · doi:10.1007/s002130050649 · Cited by 97 · cited 1×
“levels in rats, presumably by stimulating corticofugal glutamate release in the VT”
BackgroundPsychological Aspects of the Lsd Treatment of the Neuroses
Sandison, R. A. (1954) · Journal of Mental Science · doi:10.1192/bjp.100.419.508 · Cited by 97 · cited 1×
“Emphasis has also been placed on the early observation that LSD can enhance self-awareness and facilitate the recollection of, and release from, emotionally loaded memorie”
BackgroundYamauchi, M., Miyara, T., Matsushima, T., & Imanishi, T. (2005) · Brain Research · doi:10.1016/j.brainres.2005.10.075 · Cited by 89 · cited 1×
“in patients with major depression, and to be reduced after chronic treatment with various antidepressants — the reduction coinciding with the onset of clinical efficac”
BackgroundSnigdha, S., Horiguchi, M., Huang, M., Li, Z., Shahid, M., Neill, J. C., & Meltzer, H. Y. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.156349 · Cited by 88
Hallucinogen-induced relief of obsessions and compulsions
Moreno, F., & Delgado, P. L. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.7.1037b · Cited by 85
Quirk, M. C., Sosulski, D. L., Feierstein, C. E., 内田, 直., & Mainen, Z. F. (2009) · Frontiers in Systems Neuroscience · doi:10.3389/neuro.06.013.2009 · Cited by 85
The Use of LSD in Psychotherapy and Alcoholism
Cohen, S. (1967) · Psychosomatics · doi:10.1016/s0033-3182(67)71930-1 · Cited by 83
Relief of obsessive-compulsive symptoms by LSD and psilocin
Leonard, H. L., & RAPOPORT, J. L. (1987) · American Journal of Psychiatry · doi:10.1176/ajp.144.9.1239b · Cited by 81
Buckholtz, N. S., Zhou, D.-F., Freedman, D. X., & Potter, W. Z. (1990) · PubMed · Cited by 80
Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines
Winter, J. C. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1356-8 · Cited by 78
Antisense Inhibition of 5-Hydroxytryptamine2aReceptor Induces an Antidepressant-Like Effect in Mice
Sibille, E. L., Sarnyai, Z., Benjamin, D., Gál, J., Baker, H., & Tóth, M. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.6.1056 · Cited by 78 · cited 1×
“in patients with major depression, and to be reduced after chronic treatment with various antidepressants — the reduction coinciding with the onset of clinical efficac”
BackgroundAnisman, H., Merali, Z., & Stead, J. D. H. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.001 · Cited by 77 · cited 1×
“Anxiety and depression are interrelated with stres”
Agonist-Trafficking and Hallucinogens
González‐Maeso, J., & Sealfon, S. C. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709787581851 · Cited by 77
The Use of Ketamine in Psychiatry
Khorramzadeh, E., & Lotfy, A. (1973) · Psychosomatics · doi:10.1016/s0033-3182(73)71306-2 · Cited by 77
Krystal, J. H., Tolin, D. F., Sanacora, G., Castner, S. A., Williams, G. V., Aikins, D. E., Hoffman, R. E., & D'Souza, D. C. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.05.002 · Cited by 76 · cited 1×
“Normalization of these neuroplastic deficits might contribute not only to the relatively sustained antidepressant effects of ketamin”
BackgroundLambe, E. K., & Aghajanian, G. K. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300944 · Cited by 75
Zhang, C., & Marek, G. J. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.009 · Cited by 65 · cited 1×
“The increase in glutamatergic synaptic activity can be abolished not only by specific 5-HT 2A antagonists but also by AMPA (α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionic acid) receptor antagonist”
BackgroundGouzoulis‐Mayfrank, E., Habermeyer, E., Hermle, L., Steinmeyer, A., Kunert, H. J., & Sass, H. (1998) · European Psychiatry · doi:10.1016/s0924-9338(99)80686-5 · Cited by 63 · cited 1×
“— that are also seen in naturally occurring psychose”
BackgroundGresch, P. J., Smith, R. L., Barrett, R. J., & Sanders-Bush, E. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300711 · Cited by 62
LSD in the Supportive Care of the Terminally Ill Cancer Patient
Kurland, A. A. (1985) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1985.10524332 · Cited by 60
LSD THE CONSCIOUSNESS EXPANDING DRUG
SOLOMON, D. (1965) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196504000-00017 · Cited by 57
Psychedelic Therapy Utilizing LSD in the Treatment of the Alcoholic Patient: A Preliminary Report
Kurland, A. A., Unger, S. M., Shaffer, J. W., & Savage, C. (1967) · American Journal of Psychiatry · doi:10.1176/ajp.123.10.1202 · Cited by 57
LSD treatment in a severe case of compulsive neurosis
Brandrup, E., & Vanggaard, T. (1977) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1977.tb00149.x · Cited by 51 · cited 1×
“evaluated case reports and findings from studies performed in the 1960s that indicated that psilocybin and LSD are effective in the treatment of OC”
ResultKupers, R. C., Frøkjær, V. G., Naert, A., Christensen, R. H., Budtz–Jørgensen, E., Kehlet, H., & Knudsen, G. M. (2008) · NeuroImage · doi:10.1016/j.neuroimage.2008.10.011 · Cited by 49
Aghajanian, G. K. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1484-9 · Cited by 47 · cited 1×
“leads to an increase in glutamatergic recurrent network activit”
BackgroundCohen, H. (2005) · Depression and Anxiety · doi:10.1002/da.20087 · Cited by 39 · cited 1×
“In addition, chronic, antisense-mediated downregulation of 5-HT 2A receptors in rat”
BackgroundShi, W., & Zhang, X.-X. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046359 · Cited by 37 · cited 1×
“have a similar effect in enhancing extracellular glutamate release in the PFC, leading to increased activation of pyramidal cell”
BackgroundLSD: Therapeutic Effects of the Psychedelic Experience
Savage, C., Savage, E., Fadiman, J., & Harman, W. W. (1964) · Psychological Reports · doi:10.2466/pr0.1964.14.1.111 · Cited by 35
Personality Structure as the Main Determinant of Drug Induced (Model) Psychoses
Fischer, R., Marks, P. A., Hill, R. M., & Rockey, M. A. (1968) · Nature · doi:10.1038/218296a0 · Cited by 25 · cited 1×
“Depending on the individual taking the drug, their expectations, the setting in which the drug is taken and the drug dose, psychedelics produce a wide range of experiential states, from feelings of boundlessness, unity and bliss on the one hand, to the anxiety-inducing experiences of loss of ego-control and panic on t…”
BackgroundGómez‐Gil, E., Gastó, C., Carretero, M., Díaz‐Ricart, M., Salamero, M., Navinés, R., & Escolar, G. (2004) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.583 · Cited by 24
Schreckenberger, M., Gouzoulis‐Mayfrank, E., Sabri, O., Arning, C., Schulz, G., Tuttaß, T., Wagenknecht, G., Kaiser, H.-J., Saß, H., & Buell, U. (1998) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050329 · Cited by 14
FURTHER OBSERVATIONS REGARDING HALLUCINOGENIC TREATMENT
Geert-Jörgensen, E. (1968) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1968.tb01990.x · Cited by 13
Schmiege, G. R. (1963) · PubMed · Cited by 6
The joint French-US seminar on phencyclidine and related arylcyclohexylamines
Domino, E. F., Kamenka, J. M., & GENESTE, P. (1983) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(83)90445-5 · Cited by 4 · cited 1×
“Research into psychedelics was advanced in the mid 1960s by the finding that dissociative anaesthetics such as ketamine and phencyclidine (PCP) also produce psychedelic-like effect”
Background
Research works printed but not linked: 6
- Hofmann, A. in Chemical Constitution and Pharmacodynamic Actions (ed. Burger, A.) 169–235 (M.Dekker, New York, 1968).
- Dittrich, A. in 50 Years of LSD. Current Status and Perspectives of Hallucinogens (eds Pletscher, A. & Ladewig, D.) 101–118 (Parthenon, New York, 1994).
- Hoffer, A. in The Uses and Implications of Hallucinogenic Drugs (eds Aaronson, B. & Osmond, H.) 357–366 (Hogarth Press, London, 1970).
- Leuner, H. in 50 Years of LSD: Current Status and Perspectives of Hallucinogen Research (eds Pletscher, A. & Ladewig, D.) 175–189 (Parthenon, New York, 1994).
- Crocket, R., Sandison, R. A. & Walk, A. in Proc. R. Med–Psychol. Assoc. (Lewis & Co., London, 1963).
- Leuner H. in Ethnopsychotherapie (eds Dittrich, A. & Scharfetter, C.) 151–161 (Enke, Stuttgard, 1987)
Cited by
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
“As a 5-HT2A agonist, the psilocybin metabolite psilocin directly and indirectly affects various brain cortical and subcortical areas and alters brain network dynamics (Carhart-Harris et al., 2012, 2014; Vollenweider and Kometer, 2010).”
BackgroundNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
“Vollenweider and Kometer (2010) suggested that indirect activation of glutamate networks by classic psychedelics may enhance neuroplasticity through stimulation of a-amino-3-hydroxy-5-methyl-4isoxazolepropionic acid–type glutamate receptors and subsequent increase in the level of BDNF. SerumBDNF…”
BackgroundRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
“Together, these data suggest that 5HT2A downregulation may explain some of the rapid and sustained anxiolytic effects of psilocybin (Vollenweider and Kometer, 2010).”
BackgroundEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
“This indirect evidence has led to the reasonable hypothesis that psychedelics promote structural and functional neural plasticity, although this assumption had never been rigorously tested (Bogenschutz and Pommy, 2012; Vollenweider and Kometer, 2010).”
Background
Metadata
- Authors
- Vollenweider, F. X., & Kometer, M.
- Affiliations
- University of Zurich (CH)
- University Hospital Zurich (CH)
- Corresponding author
- Vollenweider, Franz X.
- Venue
- Nature Reviews Neuroscience
- Published
- 2010-08-18
- Volume
- 11
- Issue
- 9
- Pages
- 642-651
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2068751924
- Semantic Scholar
- d95a57f4b1e3288f21a7dab08ebc2fd5ff10a762
- Cited by
- 723
- References
- 149
- Citations by year
- 2026: 55 · 2025: 75 · 2024: 55 · 2023: 64 · 2022: 53 · 2021: 63 · 2020: 50 · 2019: 35 · 2018: 56 · 2017: 37 · 2016: 48 · 2015: 29 · 2014: 24 · 2013: 18 · 2012: 25
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- psychedelics, mood disorders, serotonergic system, glutamatergic system, dissociative anesthetics, LSD, psilocybin, ketamine, neuroplasticity, neural circuits, psychiatric treatment
- MeSH terms
- Animals, Brain, Hallucinogens, Humans, Models, Neurological, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.